Rationale and Design of the DIGIT-HF Trial (DIGitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure): A Randomized, Double-Blind, Placebo-Controlled Study
Udo Bavendiek(Medizinische Hochschule Hannover), Johann Bauersachs(Medizinische Hochschule Hannover), Michael Böhm(Saarland University), Armin Koch(Medizinische Hochschule Hannover), Ralf Westenfeld(Düsseldorf University Hospital), Christian Veltmann(University of Bremen), Kristina Weber(Medizinische Hochschule Hannover), Lukas Aguirre Dávila(Medizinische Hochschule Hannover), Andreas Rieth(Kerckhoff Klinik), Christoph Schröder(Medizinische Hochschule Hannover), Maximiliane Oldhafer(Medizinische Hochschule Hannover), Anja Hänselmann(Odense University Hospital), Dominik Berliner(Medizinische Hochschule Hannover), Stefan Störk(Berlin-Brandenburger Centrum für Regenerative Therapien), Lars S. Maier(University Hospital Regensburg), Sebastian Philipp(Elbe Kliniken Stade-Buxtehude), Christopher Piorkowski(Leipzig Heart Institute), Johannes Schwab(MRC Laboratory of Molecular Biology), Heiko von der Leyen(Hannover Clinical Trial Center (Germany)), Sven Schallhorn(Medizinische Hochschule Hannover)
Cited by 82
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k